Welcome to our dedicated page for Sana Biotechnology news (Ticker: SANA), a resource for investors and traders seeking the latest updates and insights on Sana Biotechnology stock.
Sana Biotechnology, Inc. (NASDAQ: SANA) is a biotechnology company focused on creating and delivering engineered cells as medicines, and its news flow reflects this emphasis on cell and gene-based therapies. Company press releases and updates describe progress across its hypoimmune platform for allogeneic cell therapies and its fusogen platform for in vivo delivery of genetic payloads.
Investors following SANA news can read about clinical and preclinical milestones in type 1 diabetes, B-cell cancers, and B-cell–mediated autoimmune diseases. Sana has reported investigator-sponsored clinical data for UP421, a primary human pancreatic islet cell therapy engineered with hypoimmune technology, including results showing survival and function of transplanted beta cells without immunosuppression. News items also cover development of SC451, an O-negative, HIP-modified, iPSC-derived pancreatic islet cell therapy, and in vivo CAR T candidates such as SG299 and SG293 built on the fusogen platform.
In addition to scientific and clinical updates, Sana’s news includes quarterly financial results, portfolio prioritization decisions, and capital-raising activities through public offerings and at-the-market equity programs. The company also issues announcements about participation in healthcare and investor conferences, where management provides business overviews and program updates.
This news page aggregates these disclosures so readers can monitor developments in Sana’s engineered cell programs, regulatory interactions, scientific publications, and financing events associated with the SANA stock. For investors and observers of the biotechnology sector, the SANA news stream offers insight into how the company is advancing its platforms and concentrating resources on type 1 diabetes and in vivo CAR T approaches.
Sana Biotechnology (NASDAQ: SANA) announced an oral presentation of preclinical data for SG293, its CD19-directed in vivo CAR T candidate, accepted at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, May 11–15, 2026 in Boston.
The presentation, titled "Potent, safe, and cell-specific in vivo generation of CAR-T cells in NHPs with SG293", is scheduled for May 12, 2026, 8:15–8:30 a.m. ET during the session on advancing in vivo gene delivery with non-AAV viral vector systems (Abstract No. 20; MCEC Room 257AB).
Sana Biotechnology (NASDAQ: SANA) and Mayo Clinic announced a strategic collaboration to accelerate development and delivery of SC451, Sana’s investigational hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. Initial work will standardize handling, surgical technique, trial design, biomarkers, and post-treatment care.
As part of the agreement, Mayo Clinic will make an equity investment in Sana and has an option for an additional investment, supporting planned clinical trial start targeted for 2026.
Cell therapy manufacturing focus is shifting from clinical data to production capability. The market is projected to nearly double to >$14B by 2035, driven by automation and FDA flexible CMC oversight. Avaí Bio (OTCQB: AVAI) completed MCB preparations in February and began MCB production with Austrianova, supporting its α-Klotho program. Vericel received FDA approval to start commercial MACI manufacturing at Burlington in Q2 2026. Eledon (NASDAQ: ELDN) reported investigator-led islet transplant data with 10 patients >4 weeks post-transplant achieving insulin independence and mean HbA1c ~5.35%.
Sana Biotechnology (NASDAQ: SANA) reported 14-month follow-up from a first-in-human, investigator-sponsored study transplanting HIP-modified primary islet cells (UP421) into a patient with type 1 diabetes without immunosuppression.
The transplanted cells showed sustained survival and function, with fasting and MMTT-stimulated C-peptide present at month 14, comparable to the first six months; no safety issues were identified. Sana expects to file an IND for SC451 and initiate a Phase 1 trial as early as this year. Full 14-month data are being presented at ATTD on March 13, 2026.
Sana Biotechnology (NASDAQ: SANA) reported Q4 and full‑year 2025 results, highlighting clinical progress and financing. Key points: UP421 showed one‑year survival and function of hypoimmune islet cells without immunosuppression; NEJM published 12‑week results. Sana raised aggregate gross proceeds of $133.7M, held $138.4M cash at year‑end, and expects runway into late 2026. Company expects IND filing and Phase 1 start for SC451 and first‑in‑human data for SG293 as early as 2026. Reported R&D spend decline and a $44.6M impairment tied to facility strategy.
Sana Biotechnology (NASDAQ: SANA) will present live at two investor conferences in March 2026, with webcasts and 30-day replays available.
Sana will present a business overview and update at the Cowen 46th Annual Health Care Conference on March 2, 2026 at 1:10 p.m. ET and at the Citizens Life Sciences Conference on March 11, 2026 at 1:40 p.m. ET. Webcasts are on the company Investor Relations page and replays remain for 30 days.
Sana Biotechnology (NASDAQ: SANA) appointed Brian Piper as Executive Vice President, Chief Financial Officer effective Feb. 17, 2026. Mr. Piper brings more than 25 years of biopharma finance and operations experience, including CFO roles at Scorpion Therapeutics, Antares Therapeutics, Prelude, and Aevi.
The company expects initial clinical data in 12–18 months for SC451 (type 1 diabetes) and SG293 (B‑cell related disease); management says Piper will help manage capital formation, allocation, and operational execution as these programs advance.
Sana Biotechnology (NASDAQ: SANA) will present at the 44th Annual J.P. Morgan Healthcare Conference with a live webcast on Wednesday, January 14, 2026 at 9:45 a.m. PT.
The presentation will include a business overview and update delivered by Steve Harr, president and chief executive officer. The webcast and a replay will be available on Sana's Investor Relations website, with the replay accessible for 30 days after the conference.
Sana Biotechnology (NASDAQ: SANA) reported that Nature Biotechnology published preclinical data showing systemic, in vivo gene editing of human hematopoietic stem and progenitor cells (HSCs) in murine models using Sana’s fusogen virus-like particle (VLP) platform (DOI: 10.1038/s41587-025-02915-2) on Dec 8, 2025. Results demonstrate potent, cell-specific editing in long-term HSCs, editing at two hemoglobinopathy-relevant loci including fetal hemoglobin, and avoidance of off-target delivery to hepatocytes. Sana said the fusogen platform now expands beyond T cells to HSCs and is being used to develop SG293 (a CD8-targeted fusosome to make CD19 CAR T cells in vivo) with an IND filing expected as early as 2027.
Sana Biotechnology (NASDAQ: SANA) will webcast presentations at two investor conferences in December 2025 featuring a business overview and update by Steve Harr, President and CEO.
Sana will present at Citi’s 2025 Global Healthcare Conference on Dec 2, 2025 at 2:30 p.m. ET and at the 8th Annual Evercore Healthcare Conference on Dec 3, 2025 at 2:35 p.m. ET. Live webcasts and replays will be available on Sana’s Investor Relations page at https://sana.com/, with each replay accessible for 30 days after the conference.